Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

Corporate Breaking News

Home : Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

Jun 22 2021	Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®
SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient in Europe in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being...


Source:https://www.prnewswire.com:443/news-releases/asieris-announces-first-patient-treated-in-europe-in-apricity-the-multinational-phase-iii-clinical-trial-of-apl-1702-cevira-301316927.html

Related News
» Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) » Targovax receives Fast Track designation for ONCOS-102 in melanoma